Results 141 to 150 of about 2,640 (193)

Repurposing Drugs for Malaria through a Human Dose Prediction: A Case Study with Berzosertib

Clinical Pharmacology &Therapeutics, EarlyView.
Repurposing drugs whose clinical safety has been established offers a valuable approach to reduce the cost and time associated with the development of new drugs for malaria. Here, we investigate the potential to repurpose the anticancer kinase inhibitor berzosertib for the treatment of malaria, by assessing whether a predicted efficacious human dose ...
Devasha Redhi, Mwila Mulubwa, Mmakwena M. Mmonwa, Mathew Njoroge, Liezl Krugmann, Kelly Chibale   +5 more
wiley   +1 more source

[Integrated care for long-responder women with metastatic breast cancer: Expert opinion for long term management in spain]. [PDF]

Aten Primaria
González V, Martínez Martínez MT, Sanmartín A, de la Haba-Rodríguez JR, Martínez Denaro D, López A.   +5 more
europepmc   +1 more source

Navigating the Prescription Drug Information System

Clinical Pharmacology &Therapeutics, EarlyView.
Information on new prescription drugs is increasingly complex and fragmented, posing challenges for healthcare professionals, patients, and payers. Clinicians require concise, actionable guidance to support prescribing decisions, while patients seek to balance benefits and harms when making decisions aligned with their treatment goals.
Irina V. Wang, Courtney Davis, Robin Forrest, Avi Cherla, Maximilian Siebert, Janice Cowden, Sophia Walker, Tamar Krishnamurti, Florence T. Bourgeois, Steven Woloshin, Anita K. Wagner, Huseyin Naci   +11 more
wiley   +1 more source

[Neurodevelopmental and Movement Disorder Due to a Mutation in the GNAO1 Gene: A Case Report]. [PDF]

Rev Neurol
Hernández Yeneris SM, González-Solano MA, Lince-Rivera I, Rojas-Martínez JA, Ramón-Gómez JL.   +4 more
europepmc   +1 more source

Adverse Reactions Identified after Approval of Novel Medicines: Analysis of 339 New Molecular Entities and Therapeutic Biologics

Clinical Pharmacology &Therapeutics, EarlyView.
Postmarketing safety surveillance data identify safety issues not identified in preapproval clinical trials. We describe the frequency of new safety issues overall and by labeling section and the relationship of the most commonly added safety issues with the cumulative number of prescriptions dispensed via retail pharmacies.
Ellen Pinnow, Brendan Day, Esther H. Zhou, Corinne Woods, Nana Dwumfour, Jenni Y. Lee, Ilynn Bulatao, Sanae Cherkaoui, Manish Kalaria, Sonja Brajovic, Nabila Sadiq, Farideh Sistani, Maggie Lee, Grace Chai, Gerald Dal Pan   +14 more
wiley   +1 more source

[CefaleApp: A Mobile Application for Migraine Diagnosis in Primary Health Care]. [PDF]

Rev Neurol
García-Estévez DA, Pérez-Schofield BG, Sabbagh Casado NA.   +2 more
europepmc   +1 more source

Early and High‐Dose Glucocorticoid Use and Survival in Advanced NSCLC Receiving Immune Checkpoint Inhibitors: A Multicenter Target Trial Emulation

Clinical Pharmacology &Therapeutics, EarlyView.
Despite the immunomodulatory mechanism of immune checkpoint inhibitors (ICIs), systemic glucocorticoids are commonly used in advanced non–small cell lung cancer (NSCLC). Evidence regarding their effects on ICI outcomes is inconsistent, in part due to confounding by indication and immortal time bias.
Da Eun Lee, Geunho Lim, Minoh Ko, Mari Kim, Ji Sun Chun, Borim Lee, Miso Kim, Kwangsoo Kim, Byung Kwan Choi, Jeongmin Seo, Jin Hyoung Kang, Taehoon Ko, In‐Wha Kim, Jung Mi Oh   +13 more
wiley   +1 more source

Organization of a Pediatric Scoliosis Surgery Task Force and Analysis of Clinical and Radiographic Outcomes. [PDF]

Rev Bras Ortop (Sao Paulo)
Bitencourt Júnior CAB, Pratali RR, Lira RCA, Morais SV, Araújo AMM, Herrero CFPDS.   +5 more
europepmc   +1 more source

Population Pharmacokinetics and Exposure‐Response Analyses to Support Cofetuzumab Pelidotin (ABBV‐647) Dose Optimization in Non‐Small Cell Lung Cancer Patients

Clinical Pharmacology &Therapeutics, EarlyView.
Cofetuzumab pelidotin (Cofe‐P) is an anti‐protein tyrosine kinase 7 (PTK7) antibody‐drug conjugate (ADC) being investigated for the treatment of adults with PTK7‐expressing, recurrent non‐small cell lung cancer (NSCLC). The first‐in‐human (FIH) trial demonstrated tolerability of dosages ≤ 2.8 mg/kg once every 3 weeks (Q3W) and ≤ 3.2 mg/kg Q2W ...
Carla Biesdorf, Melanie Rinas, Benjamin Engelhardt, Rabih Saab, Cen Guo, Cristiano Ferlini, Kevin J. Freise, Rajeev M. Menon, Akshanth R. Polepally   +8 more
wiley   +1 more source

Náusea y vómito postoperatorio en pacientes sometidos a cirugía de mama

Revista Chilena de Anestesia, 2019
Giancarlo Ferretiz G., Neftalí Cárdenas   +1 more
doaj   +1 more source